Nanobodies as therapeutics: big opportunities for small antibodies.

[1]  G. Decavalas,et al.  Severe Sepsis and Septic Shock , 2018 .

[2]  Alexander K. Buell,et al.  Vrije Universiteit Brussel Nanobodies Raised against Monomeric alpha-Synuclein Distinguish between Fibrils at Different Maturation Stages , 2017 .

[3]  C. Vanhove,et al.  Targeting of vascular cell adhesion molecule-1 by 18F-labelled nanobodies for PET/CT imaging of inflamed atherosclerotic plaques. , 2016, European heart journal cardiovascular Imaging.

[4]  A. Kilcoyne,et al.  Molecular imaging-its current role in cancer. , 2016, QJM : monthly journal of the Association of Physicians.

[5]  Y. Saeys,et al.  Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  M. Rajabibazl,et al.  Camelid‐derived heavy‐chain nanobody against Clostridium botulinum neurotoxin E in Pichia pastoris , 2016, Biotechnology and applied biochemistry.

[7]  R. Schiffelers,et al.  PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[8]  C. Dullin,et al.  In vivo detection of small tumour lesions by multi-pinhole SPECT applying a 99mTc-labelled nanobody targeting the Epidermal Growth Factor Receptor , 2016, Scientific Reports.

[9]  H. Lyerly,et al.  Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET , 2016, The Journal of Nuclear Medicine.

[10]  H. Ploegh,et al.  Structurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma. , 2016, Angewandte Chemie.

[11]  B. Jilma,et al.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. , 2016, The New England journal of medicine.

[12]  Sabrina Oliveira,et al.  Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization , 2016, EJNMMI Research.

[13]  Melanie A. Huntley,et al.  Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies , 2016, Neuron.

[14]  C. Vanhove,et al.  Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma , 2016, The Journal of Nuclear Medicine.

[15]  M. Zalutsky,et al.  Preclinical Evaluation of 18 F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by ImmunoPET , 2016 .

[16]  R. Tao,et al.  A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2‐Positive Breast Cancer Cells , 2016, Chembiochem : a European journal of chemical biology.

[17]  E. Zhou,et al.  An intracellularly expressed Nsp9-specific nanobody in MARC-145 cells inhibits porcine reproductive and respiratory syndrome virus replication. , 2015, Veterinary microbiology.

[18]  A. de Marco,et al.  Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study. , 2015, Journal of biotechnology.

[19]  W. Mali,et al.  Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer , 2015, Molecular Imaging and Biology.

[20]  Jonathan S. Mason,et al.  Structures of G protein-coupled receptors reveal new opportunities for drug discovery. , 2015, Drug discovery today.

[21]  C. Palomo,et al.  Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection , 2015, Antimicrobial Agents and Chemotherapy.

[22]  N. Mantis,et al.  Mechanisms of Ricin Toxin Neutralization Revealed through Engineered Homodimeric and Heterodimeric Camelid Antibodies* , 2015, The Journal of Biological Chemistry.

[23]  Baorui Liu,et al.  A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  K. Bok,et al.  Llama Nanoantibodies with Therapeutic Potential against Human Norovirus Diarrhea , 2015, PloS one.

[25]  Michel Goedert,et al.  Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein , 2015, Science.

[26]  Guy Bormans,et al.  PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments , 2015, The Journal of Nuclear Medicine.

[27]  A. González-Techera,et al.  Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain , 2015, mAbs.

[28]  G. Koning,et al.  A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[29]  B. Strukelj,et al.  Non-immunoglobulin scaffolds: a focus on their targets. , 2015, Trends in biotechnology.

[30]  Yanli Guo,et al.  Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging , 2015, PloS one.

[31]  M. Rajabibazl,et al.  Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF , 2015, Applied Biochemistry and Biotechnology.

[32]  M. Cristina Cardoso,et al.  Nanobodies and recombinant binders in cell biology , 2015, The Journal of cell biology.

[33]  I. Nabiev,et al.  Detection of carcinoembryonic antigen using single-domain or full-size antibodies stained with quantum dot conjugates. , 2015, Analytical biochemistry.

[34]  P. Skottrup,et al.  Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator. , 2015, Molecular immunology.

[35]  H. D. de Koning,et al.  Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis , 2015, PLoS pathogens.

[36]  B. '. ’t Hart,et al.  The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis , 2015, Arthritis Research & Therapy.

[37]  Yakun Wan,et al.  Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library , 2015, Journal of Nanobiotechnology.

[38]  Ralph Weissleder,et al.  Noninvasive imaging of immune responses , 2015, Proceedings of the National Academy of Sciences.

[39]  Min Wu,et al.  A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting , 2015, International journal of nanomedicine.

[40]  M. Dumoulin,et al.  Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena. , 2015, Biochimie.

[41]  P. Srimanote,et al.  Humanized-VHH Transbodies that Inhibit HCV Protease and Replication , 2015, Viruses.

[42]  A. Desmyter,et al.  Inhibition of Type VI Secretion by an Anti-TssM Llama Nanobody , 2015, PloS one.

[43]  Lei Chen,et al.  CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants. , 2015, The Journal of general virology.

[44]  Baorui Liu,et al.  Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[45]  K. Papadopoulos,et al.  Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor , 2015, Cancer Chemotherapy and Pharmacology.

[46]  E. Pardon,et al.  Structural insight in the inhibition of adherence of F4 fimbriae producing enterotoxigenic Escherichia coli by llama single domain antibodies , 2015, Veterinary Research.

[47]  S. Muyldermans,et al.  Monitoring liver macrophages using nanobodies targeting Vsig4: concanavalin A induced acute hepatitis as paradigm. , 2015, Immunobiology.

[48]  S. Charlton,et al.  Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action , 2015, Molecular Pharmacology.

[49]  S. Hussain,et al.  Description of a Nanobody-based Competitive Immunoassay to Detect Tsetse Fly Exposure , 2015, PLoS neglected tropical diseases.

[50]  Asher Mullard.  2014 FDA drug approvals , 2015, Nature Reviews Drug Discovery.

[51]  S. Achilefu,et al.  Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy , 2015, Theranostics.

[52]  H. Rohde,et al.  Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT , 2015, Scientific Reports.

[53]  S. Oliveira,et al.  Nanobody-based cancer therapy of solid tumors. , 2015, Nanomedicine.

[54]  W. Derave,et al.  An ER-directed gelsolin nanobody targets the first step in amyloid formation in a gelsolin amyloidosis mouse model. , 2015, Human molecular genetics.

[55]  Miguel Soriano,et al.  Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[56]  S. Leppla,et al.  A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model* , 2015, The Journal of Biological Chemistry.

[57]  F. Koch-Nolte,et al.  ADP-ribosylation of P2X7: a matter of life and death for regulatory T cells and natural killer T cells. , 2015, Current topics in microbiology and immunology.

[58]  G. Norata,et al.  HDL in infectious diseases and sepsis. , 2015, Handbook of experimental pharmacology.

[59]  Michelle E. Hung,et al.  Designed Ankyrin Repeat Proteins ( DARPins ) : Binding Proteins for Research , Diagnostics , and Therapy , 2015 .

[60]  B. Devreese,et al.  Generation of a Nanobody Targeting the Paraflagellar Rod Protein of Trypanosomes , 2014, PloS one.

[61]  H. Ploegh,et al.  Intracellular Expression of Camelid Single-Domain Antibodies Specific for Influenza Virus Nucleoprotein Uncovers Distinct Features of Its Nuclear Localization , 2014, Journal of Virology.

[62]  Martine De Vos,et al.  Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1* , 2014, The Journal of Biological Chemistry.

[63]  Yakun Wan,et al.  Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1 , 2014, Journal of Translational Medicine.

[64]  G. Hansman,et al.  Nanobody Binding to a Conserved Epitope Promotes Norovirus Particle Disassembly , 2014, Journal of Virology.

[65]  E. Pardon,et al.  Nanobody Mediated Inhibition of Attachment of F18 Fimbriae Expressing Escherichia coli , 2014, PloS one.

[66]  B. Gamain,et al.  Llama immunization with full-length VAR2CSA generates cross-reactive and inhibitory single-domain antibodies against the DBL1X domain , 2014, Scientific Reports.

[67]  E. Vanstreels,et al.  A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. , 2014, Antiviral research.

[68]  Robin A. Weiss,et al.  Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1 , 2014, PLoS pathogens.

[69]  G. Caljon,et al.  Delivery of a functional anti-trypanosome Nanobody in different tsetse fly tissues via a bacterial symbiont, Sodalis glossinidius , 2014, Microbial Cell Factories.

[70]  J. Eldredge,et al.  A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  I. Nabiev,et al.  Multiphoton imaging of tumor biomarkers with conjugates of single-domain antibodies and quantum dots. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[72]  Julia Maier,et al.  Recent progress in generating intracellular functional antibody fragments to target and trace cellular components in living cells. , 2014, Biochimica et biophysica acta.

[73]  W. Sellers,et al.  Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction , 2014, mAbs.

[74]  G. van Ommen,et al.  Selection and characterization of llama single domain antibodies against N-terminal huntingtin , 2014, Neurological Sciences.

[75]  Sabrina Oliveira,et al.  Nanobody-photosensitizer conjugates for targeted photodynamic therapy. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[76]  Gilles Barone-Rochette,et al.  99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice , 2014, The Journal of Nuclear Medicine.

[77]  B. Aggarwal.  Editorial: Balancing Tumor Necrosis Factor Receptor I and Tumor Necrosis Factor Receptor II Jointly for Joint Inflammation , 2014, Arthritis & rheumatology.

[78]  E. Lerma,et al.  Thrombotic thrombocytopenic purpura. , 2014, Disease-a-month : DM.

[79]  J. Vandekerckhove,et al.  Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[80]  M. Fink,et al.  Strategies to improve drug development for sepsis , 2014, Nature Reviews Drug Discovery.

[81]  J. Tommassen,et al.  Inhibition of biofilm formation by Camelid single-domain antibodies against the flagellum of Pseudomonas aeruginosa. , 2014, Journal of biotechnology.

[82]  Yakun Wan,et al.  Combining magnetic nanoparticle with biotinylated nanobodies for rapid and sensitive detection of influenza H3N2 , 2014, Nanoscale Research Letters.

[83]  F. Koch-Nolte,et al.  Nanobodies as modulators of inflammation: potential applications for acute brain injury , 2014, Front. Cell. Neurosci..

[84]  S. Muyldermans,et al.  Interactions between Metal-binding Domains Modulate Intracellular Targeting of Cu(I)-ATPase ATP7B, as Revealed by Nanobody Binding* , 2014, The Journal of Biological Chemistry.

[85]  R. Stábeli,et al.  Novel Camelid Antibody Fragments Targeting Recombinant Nucleoprotein of Araucaria hantavirus: A Prototype for an Early Diagnosis of Hantavirus Pulmonary Syndrome , 2014, PloS one.

[86]  D. Schmidt,et al.  A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. , 2014, The Journal of infectious diseases.

[87]  N. Iqbal,et al.  Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications , 2014, Molecular biology international.

[88]  D. Curiel,et al.  Prolonged Prophylactic Protection from Botulism with a Single Adenovirus Treatment Promoting Serum Expression of a VHH-Based Antitoxin Protein , 2014, PloS one.

[89]  M. Rudolph,et al.  Crystal structures of ricin toxin's enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies. , 2014, Journal of molecular biology.

[90]  S. Muyldermans,et al.  Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer , 2014, Expert opinion on drug delivery.

[91]  M. Tayebi,et al.  Potential candidate camelid antibodies for the treatment of protein-misfolding diseases , 2014, Journal of Neuroimmunology.

[92]  T. Baral,et al.  In vivo imaging of brain cancer using epidermal growth factor single domain antibody bioconjugated to near-infrared quantum dots. , 2014, Journal of nanoscience and nanotechnology.

[93]  S. Muyldermans,et al.  A nanobody-based electrochemiluminescent immunosensor for sensitive detection of human procalcitonin. , 2014, The Analyst.

[94]  N. Devoogdt,et al.  Camelid reporter gene imaging: a generic method for in vivo cell tracking , 2014, EJNMMI Research.

[95]  H. Walczak,et al.  Getting TRAIL back on track for cancer therapy , 2014, Cell Death and Differentiation.

[96]  S. Maier,et al.  Highly sensitive single domain antibody-quantum dot conjugates for detection of HER2 biomarker in lung and breast cancer cells. , 2014, ACS nano.

[97]  N. Mantis,et al.  Differential Neutralizing Activities of a Single Domain Camelid Antibody (VHH) Specific for Ricin Toxin’s Binding Subunit (RTB) , 2014, PloS one.

[98]  S. Muyldermans,et al.  A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[99]  K. van Beneden,et al.  FRI0329 Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with Alx-0061: Post-Hoc Analysis of Phase I/Ii Data , 2014 .

[100]  A. Vahrmeijer,et al.  Intraoperative fluorescence delineation of head and neck cancer with a fluorescent Anti‐epidermal growth factor receptor nanobody , 2014, International journal of cancer.

[101]  A. Riazi,et al.  Protease-resistant single-domain antibodies inhibit Campylobacter jejuni motility. , 2014, Protein engineering, design & selection : PEDS.

[102]  S. Muyldermans,et al.  Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging. , 2014, Bioconjugate chemistry.

[103]  M. Smit,et al.  GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics. , 2014, Trends in pharmacological sciences.

[104]  S. Muyldermans,et al.  Nanobody-based products as research and diagnostic tools. , 2014, Trends in biotechnology.

[105]  S. Muyldermans,et al.  Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. , 2014, Contrast media & molecular imaging.

[106]  S. Muyldermans,et al.  Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis , 2014, The Journal of Nuclear Medicine.

[107]  L. Hammarström,et al.  Co-Expression of Anti-Rotavirus Proteins (Llama VHH Antibody Fragments) in Lactobacillus: Development and Functionality of Vectors Containing Two Expression Cassettes in Tandem , 2014, PloS one.

[108]  S. Muyldermans,et al.  Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody , 2014, Theranostics.

[109]  C. Dobson,et al.  Oligomer-targeting with a conformational antibody fragment promotes toxicity in Aβ-expressing flies , 2014, Acta neuropathologica communications.

[110]  H. Kiyono,et al.  A rice-based soluble form of a murine TNF-specific llama variable domain of heavy-chain antibody suppresses collagen-induced arthritis in mice. , 2014, Journal of biotechnology.

[111]  S. Muyldermans,et al.  Specific Targeting of Atherosclerotic Plaques in ApoE−/− Mice Using a New Camelid sdAb Binding the Vulnerable Plaque Marker LOX-1 , 2014, Molecular Imaging and Biology.

[112]  H. Lyerly,et al.  Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling , 2014, The Journal of Nuclear Medicine.

[113]  D. Ahmadvand,et al.  A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment. , 2014, Biochemical and biophysical research communications.

[114]  G. Adam,et al.  In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies. , 2014, Contrast media & molecular imaging.

[115]  S. Muyldermans,et al.  A general protocol for the generation of Nanobodies for structural biology , 2014, Nature Protocols.

[116]  F. Koch-Nolte,et al.  Technical Advance: A new cell preparation strategy that greatly improves the yield of vital and functional Tregs and NKT cells , 2014, Journal of leukocyte biology.

[117]  J. Tavernier,et al.  The Anti-Tumor Activity of a Neutralizing Nanobody Targeting Leptin Receptor in a Mouse Model of Melanoma , 2014, PloS one.

[118]  D. Filman,et al.  Mechanism of Action and Capsid-Stabilizing Properties of VHHs with an In Vitro Antipolioviral Activity , 2014, Journal of Virology.

[119]  M. Rajabibazl,et al.  Functional Mutations in and Characterization of VHH Against Helicobacter pylori Urease , 2014, Applied Biochemistry and Biotechnology.

[120]  I. Rasooli,et al.  Immunoreaction of a recombinant nanobody from camelid single domain antibody fragment with Acinetobacter baumannii. , 2014, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[121]  S. Muyldermans,et al.  Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies , 2014, Leukemia.

[122]  Rubel Chakravarty,et al.  Nanobody: The “Magic Bullet” for Molecular Imaging? , 2014, Theranostics.

[123]  N. Harris,et al.  The heavy chain diseases: clinical and pathologic features. , 2014, Oncology.

[124]  J. Tavernier,et al.  High efficiency cell-specific targeting of cytokine activity , 2014, Nature Communications.

[125]  Giuseppe Legname,et al.  Probing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobody. , 2014, Journal of the American Chemical Society.

[126]  Xiaomin Wang,et al.  Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor , 2014, Scientific Reports.

[127]  F. Lavorini,et al.  Inhaler technique and patient's preference for dry powder inhaler devices , 2014, Expert opinion on drug delivery.

[128]  E. Pardon,et al.  Probing the N-Terminal beta-Sheet Conversion in the Crystal Structure of the Human Prion Protein Bound to a Nanobody Abskharon, , 2014 .

[129]  G. Farrington,et al.  Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. , 2014, Advances in pharmacology.

[130]  M. Shokrgozar,et al.  T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. , 2014, Biochimica et biophysica acta.

[131]  B. Aggarwal.  Balancing TNFR 1 and TNFR 2 Jointly for Joint Inflammation , 2014 .

[132]  W. Hennink,et al.  Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles. , 2014, Biomaterials.

[133]  S. Benichou,et al.  Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody , 2014, Retrovirology.

[134]  C. Szymanski,et al.  Pentavalent Single-Domain Antibodies Reduce Campylobacter jejuni Motility and Colonization in Chickens , 2013, PloS one.

[135]  Sabrina Oliveira,et al.  Targeting tumors with nanobodies for cancer imaging and therapy. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[136]  O. De Wever,et al.  A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis , 2013, Breast Cancer Research.

[137]  N. Mantis,et al.  Stepwise Engineering of Heterodimeric Single Domain Camelid VHH Antibodies That Passively Protect Mice from Ricin Toxin* , 2013, The Journal of Biological Chemistry.

[138]  T. Standal,et al.  Anti‐c‐MET Nanobody® – a new potential drug in multiple myeloma treatment , 2013, European journal of haematology.

[139]  N. Levy,et al.  Preferential Lentiviral Targeting of Astrocytes in the Central Nervous System , 2013, PloS one.

[140]  L. Hammarström,et al.  Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial. , 2013, Gastroenterology.

[141]  S. Tzipori,et al.  A Single VHH-Based Toxin-Neutralizing Agent and an Effector Antibody Protect Mice against Challenge with Shiga Toxins 1 and 2 , 2013, Infection and Immunity.

[142]  K. Omidfar,et al.  Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody , 2013, Molecular Biology Reports.

[143]  M. Oyama,et al.  Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. , 2013, The Journal of clinical investigation.

[144]  M. Buyse,et al.  ALX-0962, an anti-IgE Nanobody® with a dual mode of action , 2013 .

[145]  M. R. Bazl,et al.  A novel nanobody against urease activity of Helicobacter pylori. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[146]  A. Meola,et al.  An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission , 2013, Hepatology.

[147]  G. V. van Dongen,et al.  Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in Vivo , 2013, The Journal of Biological Chemistry.

[148]  C. Verlinde,et al.  The structure of the D3 domain of Plasmodium falciparum myosin tail interacting protein MTIP in complex with a nanobody. , 2013, Molecular and biochemical parasitology.

[149]  Carla P. Guimarães,et al.  Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions , 2013, Nature Protocols.

[150]  Alexander K. Buell,et al.  Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages. , 2013, Journal of molecular biology.

[151]  Michael D. McLean,et al.  In Vivo Neutralization of α-Cobratoxin with High-Affinity Llama Single-Domain Antibodies (VHHs) and a VHH-Fc Antibody , 2013, PloS one.

[152]  P. De Baetselier,et al.  Targeting of Human Antigen-Presenting Cell Subsets , 2013, Journal of Virology.

[153]  S. Muyldermans,et al.  Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target , 2013, Expert opinion on biological therapy.

[154]  A. Serone,et al.  Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1 , 2013, Journal of Clinical Immunology.

[155]  S. Muyldermans,et al.  V(H)H (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays. , 2013, Analytical biochemistry.

[156]  W. Leenders,et al.  Nanobody-functionalized polymersomes for tumor-vessel targeting. , 2013, Macromolecular bioscience.

[157]  M. Shokrgozar,et al.  Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. , 2013, Cancer letters.

[158]  Sam Millet,et al.  Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic Escherichia coli infection , 2013, Proceedings of the National Academy of Sciences.

[159]  Vasilis Ntziachristos,et al.  Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[160]  B. Robert,et al.  Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells , 2013, Molecular Cancer Therapeutics.

[161]  G. Xiao,et al.  Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics , 2013, International journal of cell biology.

[162]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[163]  J. Holz,et al.  Anti-RANKL nanobody ALX-0141 shows sustained biomarker inhibition in a Phase I study in healthy postmenopausal Women , 2013 .

[164]  A. Messer,et al.  Intrabodies as Neuroprotective Therapeutics , 2013, Neurotherapeutics.

[165]  E. Brunette,et al.  Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method. , 2013, Molecular pharmaceutics.

[166]  Marleen Keyaerts,et al.  Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer , 2013, The Journal of Nuclear Medicine.

[167]  P. De Baetselier,et al.  SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis , 2013, The Journal of Nuclear Medicine.

[168]  Imre Mäger,et al.  Extracellular vesicles: biology and emerging therapeutic opportunities , 2013, Nature Reviews Drug Discovery.

[169]  L. Sherwood,et al.  Ebolavirus Nucleoprotein C-Termini Potently Attract Single Domain Antibodies Enabling Monoclonal Affinity Reagent Sandwich Assay (MARSA) Formulation , 2013, PloS one.

[170]  E. Vanstreels,et al.  Mapping the Binding Interface between an HIV-1 Inhibiting Intrabody and the Viral Protein Rev , 2013, PloS one.

[171]  T. I. Ivanova,et al.  Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). , 2013, Antiviral research.

[172]  C. Kuan,et al.  Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier , 2013, Proceedings of the National Academy of Sciences.

[173]  W. Hennink,et al.  Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[174]  S. Muyldermans,et al.  Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. , 2013, New biotechnology.

[175]  W. Wijns,et al.  Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor , 2013, Journal of Cardiovascular Translational Research.

[176]  N. Devoogdt,et al.  Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. , 2013, Nuclear medicine and biology.

[177]  S. Kiuru-Enari,et al.  Hereditary gelsolin amyloidosis. , 2013, Handbook of clinical neurology.

[178]  K. Ulbrich,et al.  Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. , 2013, Biomaterials.

[179]  M. Rajabibazl,et al.  A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis , 2013, Biotechnology Letters.

[180]  S. Muyldermans,et al.  Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies , 2012, PLoS neglected tropical diseases.

[181]  J. Holz,et al.  Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. , 2012, Blood.

[182]  S. Muyldermans,et al.  Pre-clinical studies of toxin-specific nanobodies: evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming. , 2012, Toxicology and applied pharmacology.

[183]  M. V. Roy,et al.  preclinical Development of Alx-0061, an Anti-il-6r Nanobody® for therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile. : 336 , 2012 .

[184]  J. Bourgeois,et al.  Cell‐penetrating anti‐GFAP VHH and corresponding fluorescent fusion protein VHH‐GFP spontaneously cross the blood‐brain barrier and specifically recognize astrocytes: application to brain imaging , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[185]  H. Wakimoto,et al.  Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects , 2012, Proceedings of the National Academy of Sciences.

[186]  Yi Huang,et al.  Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion , 2012, BMC Biotechnology.

[187]  S. Zeinali,et al.  Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2 , 2012, Advanced biomedical research.

[188]  C. López-Otín,et al.  Matrix Metalloprotease 8-Dependent Extracellular Matrix Cleavage at the Blood–CSF Barrier Contributes to Lethality during Systemic Inflammatory Diseases , 2012, The Journal of Neuroscience.

[189]  P. De Baetselier,et al.  Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. , 2012, Cancer research.

[190]  M. van Buchem,et al.  In Vivo Detection of Amyloid-\(\beta \) Deposits Using Heavy Chain Antibody Fragments in a Transgenic Mouse Model for Alzheimer's Disease , 2012 .

[191]  Susan Y. Smith,et al.  ALX-0141, an anti-rank-L targeting nanobody®, increases bone mass in cynomolgus monkeys , 2012 .

[192]  Igor Nabiev,et al.  Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[193]  I. Velikyan.  Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management , 2012, Theranostics.

[194]  W. Hennink,et al.  Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[195]  Y. Michotte,et al.  Using microdialysis to analyse the passage of monovalent nanobodies through the blood–brain barrier , 2012, British journal of pharmacology.

[196]  Jakub Toczek,et al.  Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions , 2012, Circulation research.

[197]  Jakub Toczek,et al.  Nanobody-coupled microbubbles as novel molecular tracer. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[198]  J. Bouma,et al.  In Vitro Neutralisation of Rotavirus Infection by Two Broadly Specific Recombinant Monovalent Llama-Derived Antibody Fragments , 2012, PloS one.

[199]  P. De Baetselier,et al.  Expression and extracellular release of a functional anti-trypanosome Nanobody® in Sodalis glossinidius, a bacterial symbiont of the tsetse fly , 2012, Microbial Cell Factories.

[200]  G. Sinha.  Ablynx drops lead nanobody , 2012, Nature Biotechnology.

[201]  H. Wong.  Clinical review: Sepsis and septic shock - the potential of gene arrays , 2012, Critical Care.

[202]  G. V. van Dongen,et al.  Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy , 2012, Molecular Cancer Therapeutics.

[203]  H. Wong,et al.  A novel role for matrix metalloproteinase-8 in sepsis* , 2012, Critical care medicine.

[204]  A. Kossiakoff,et al.  Substance P derivatives as versatile tools for specific delivery of various types of biomolecular cargo. , 2012, Bioconjugate chemistry.

[205]  P. De Baetselier,et al.  Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells , 2012, Gene Therapy.

[206]  W. Mali,et al.  Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Anti–Epidermal Growth Factor Receptor Nanobody , 2012, Molecular imaging.

[207]  D. Dimitrov,et al.  Expression, purification, and characterization of engineered antibody CH2 and VH domains. , 2012, Methods in molecular biology.

[208]  B. Bouhaouala-Zahar,et al.  Efficient expression of the anti‐AahI' scorpion toxin nanobody under a new functional form in a Pichia pastoris system , 2012, Biotechnology and applied biochemistry.

[209]  A. de Marco,et al.  Preparation of a naïve library of camelid single domain antibodies. , 2012, Methods in molecular biology.

[210]  Michaela Gebauer,et al.  Anticalins small engineered binding proteins based on the lipocalin scaffold. , 2012, Methods in enzymology.

[211]  J. Tavernier,et al.  Selection of non-competitive leptin antagonists using a random nanobody-based approach. , 2012, The Biochemical journal.

[212]  N. Devoogdt,et al.  Immuno-imaging using nanobodies. , 2011, Current opinion in biotechnology.

[213]  R. Kontermann,et al.  Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.

[214]  B. Schepens,et al.  Nanobodies®: new ammunition to battle viruses. , 2011, Antiviral research.

[215]  J. Tanha,et al.  Engineered Single-Domain Antibodies with High Protease Resistance and Thermal Stability , 2011, PloS one.

[216]  B. Hyman,et al.  Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging , 2011, Proceedings of the National Academy of Sciences.

[217]  D. Ahmadvand,et al.  Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by φC31 integrase. , 2011, Experimental cell research.

[218]  A. Verkleij,et al.  A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth , 2011, International journal of cancer.

[219]  R. Vandenbroucke,et al.  Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. , 2011, Cytokine & growth factor reviews.

[220]  S. Muyldermans,et al.  Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel. , 2011, Veterinary immunology and immunopathology.

[221]  Nick Devoogdt,et al.  Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[222]  Liesbet Lagae,et al.  Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. , 2011, ACS nano.

[223]  A. Marco.  Biotechnological applications of recombinant single-domain antibody fragments , 2011 .

[224]  A. de Marco.  Biotechnological applications of recombinant single-domain antibody fragments , 2011, Microbial cell factories.

[225]  Mark C. Field,et al.  High Affinity Nanobodies against the Trypanosome brucei VSG Are Potent Trypanolytic Agents that Block Endocytosis , 2011, PLoS pathogens.

[226]  Deming Zhao,et al.  PrPSc-Specific Antibodies with the Ability to Immunodetect Prion Oligomers , 2011, PloS one.

[227]  L. Hammarström,et al.  Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. , 2011, Future microbiology.

[228]  U. Tuor,et al.  Small unilamellar vesicles: a platform technology for molecular imaging of brain tumors , 2011, Nanotechnology.

[229]  R. Weiss,et al.  Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. , 2011, The Journal of infectious diseases.

[230]  X. Breakefield,et al.  Genetic therapy for the nervous system. , 2011, Human molecular genetics.

[231]  R. Vandenbroucke,et al.  Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. , 2011, Cytokine & growth factor reviews.

[232]  R. Weiss,et al.  Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules , 2011, PloS one.

[233]  E. Véscovi,et al.  Single‐domain llama antibodies as specific intracellular inhibitors of SpvB, the actin ADP‐ribosylating toxin of Salmonella typhimurium , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[234]  K. K. Andersen,et al.  Integrative Expression System for Delivery of Antibody Fragments by Lactobacilli , 2011, Applied and Environmental Microbiology.

[235]  L. Wyns,et al.  Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic β2-microglobulin variant , 2011, Proceedings of the National Academy of Sciences of the United States of America.

[236]  J. Tanha,et al.  Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain* , 2011, The Journal of Biological Chemistry.

[237]  Pin Wang,et al.  Immunization delivered by lentiviral vectors for cancer and infectious diseases , 2011, Immunological reviews.

[238]  G. V. van Dongen,et al.  Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[239]  S. Muyldermans,et al.  Direct Injection of Functional Single-Domain Antibodies from E. coli into Human Cells , 2010, PloS one.

[240]  R. Leurs,et al.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells , 2010, Proceedings of the National Academy of Sciences.

[241]  C. Dobson,et al.  Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. , 2010, Journal of molecular biology.

[242]  S. Muyldermans,et al.  A bispecific nanobody to provide full protection against lethal scorpion envenoming , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[243]  G. Schreiber,et al.  Cytokine-receptor interactions as drug targets. , 2010, Current opinion in chemical biology.

[244]  R. Schiffelers,et al.  Downregulation of EGFR by a novel multivalent nanobody-liposome platform. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[245]  M. During,et al.  Environmental and Genetic Activation of a Brain-Adipocyte BDNF/Leptin Axis Causes Cancer Remission and Inhibition , 2010, Cell.

[246]  S. Muyldermans,et al.  In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT , 2010, Journal of Nuclear Medicine.

[247]  Rachael D. Bernstein,et al.  Llama-derived single-domain antibodies for the detection of botulinum A neurotoxin , 2010, Analytical and bioanalytical chemistry.

[248]  Fredrik Y Frejd,et al.  Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications , 2010, FEBS letters.

[249]  Anna M Wu,et al.  Antibody vectors for imaging. , 2010, Seminars in nuclear medicine.

[250]  S. Muyldermans,et al.  Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types , 2010, Journal of Nuclear Medicine.

[251]  E. Vanstreels,et al.  An Intrabody Based on a Llama Single-domain Antibody Targeting the N-terminal α-Helical Multimerization Domain of HIV-1 Rev Prevents Viral Production* , 2010, The Journal of Biological Chemistry.

[252]  R. Weiss,et al.  Generation of a Family-specific Phage Library of Llama Single Chain Antibody Fragments That Neutralize HIV-1* , 2010, The Journal of Biological Chemistry.

[253]  Diarmaid Hughes,et al.  Antibiotic resistance and its cost: is it possible to reverse resistance? , 2010, Nature Reviews Microbiology.

[254]  C. Bate,et al.  A Camelid Anti-PrP Antibody Abrogates PrPSc Replication in Prion-Permissive Neuroblastoma Cell Lines , 2010, PloS one.

[255]  M. Jaramillo,et al.  Differential tumor-targeting abilities of three single-domain antibody formats. , 2010, Cancer letters.

[256]  F. Koch-Nolte,et al.  A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. , 2010, Journal of autoimmunity.

[257]  E. Remaut,et al.  Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis , 2010, Mucosal Immunology.

[258]  A. Kondo,et al.  Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. , 2009, Journal of biochemistry.

[259]  S. Muyldermans,et al.  Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. , 2009, The Biochemical journal.

[260]  S. Tzipori,et al.  Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents , 2009, Infection and Immunity.

[261]  Hisataka Kobayashi,et al.  Clinical implications of near-infrared fluorescence imaging in cancer. , 2009, Future oncology.

[262]  H. Revets,et al.  The development of nanobodies for therapeutic applications. , 2009, Current opinion in investigational drugs.

[263]  C. Dobson,et al.  1H, 13C and 15N assignments of a camelid nanobody directed against human α-synuclein , 2009, Biomolecular NMR assignments.

[264]  A. Kossiakoff,et al.  An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells , 2009, Proceedings of the National Academy of Sciences.

[265]  R. Scott,et al.  Head‐to‐tail fusions of camelid antibodies can be expressed in planta and bind in rumen fluid , 2009, Biotechnology and applied biochemistry.

[266]  C. Verrips,et al.  Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. , 2009, Human molecular genetics.

[267]  G. Adams,et al.  Affinity and avidity in antibody-based tumor targeting. , 2009, Cancer biotherapy & radiopharmaceuticals.

[268]  S. Muyldermans,et al.  Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. , 2009, International journal for parasitology.

[269]  L. Wyns,et al.  Camelid immunoglobulins and nanobody technology. , 2009, Veterinary immunology and immunopathology.

[270]  C. Duyckaerts,et al.  Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. , 2009, Molecular immunology.

[271]  S. Muyldermans,et al.  General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold* , 2009, Journal of Biological Chemistry.

[272]  J. Tanha,et al.  Isolation of monoclonal antibody fragments from phage display libraries. , 2009, Methods in molecular biology.

[273]  P. Choyke,et al.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.

[274]  S. Muyldermans,et al.  VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. , 2008, Molecular immunology.

[275]  C. R. Leemans,et al.  Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology , 2008, Molecular Cancer Therapeutics.

[276]  Christian Vanhove,et al.  Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT , 2008, Journal of Nuclear Medicine.

[277]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[278]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[279]  C. Vanhove,et al.  SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.

[280]  Frode Willoch,et al.  Imaging of opioid receptors in the central nervous system , 2007, Brain : a journal of neurology.

[281]  C. Sautès-Fridman,et al.  Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. , 2008, Protein engineering, design & selection : PEDS.

[282]  Michael J. Osborn,et al.  Heavy chain–only antibodies are spontaneously produced in light chain–deficient mice , 2007, The Journal of experimental medicine.

[283]  C. Sautès-Fridman,et al.  Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. , 2007, Protein engineering, design & selection : PEDS.

[284]  C. Sachse,et al.  Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils , 2007, Proceedings of the National Academy of Sciences.

[285]  Shohei Koide,et al.  Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope. , 2007, Journal of molecular biology.

[286]  Hidde L Ploegh,et al.  Sortagging: a versatile method for protein labeling. , 2007, Nature chemical biology.

[287]  F. Aires da Silva,et al.  Recombinant single-chain variable fragment and single domain antibody piezoimmunosensors for detection of HIV1 virion infectivity factor. , 2007, Biosensors & bioelectronics.

[288]  J. Stam,et al.  Improved anti-IgG and HSA affinity ligands: clinical application of VHH antibody technology. , 2007, Journal of immunological methods.

[289]  K. Shannon,et al.  Huntington's Disease: Pathological Mechanisms and Therapeutic Strategies , 2007, Cell transplantation.

[290]  Yasuyoshi Watanabe,et al.  [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.

[291]  A. Verkleij,et al.  Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies , 2007, Cancer Immunology, Immunotherapy.

[292]  James B Delehanty,et al.  Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. , 2006, Analytical chemistry.

[293]  Yaofeng Zhao,et al.  Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. , 2006, The Journal of infectious diseases.

[294]  J. Tanha,et al.  Identification of single‐domain, Bax‐specific intrabodies that confer resistance to mammalian cells against oxidative‐stress‐induced apoptosis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[295]  Heinrich Leonhardt,et al.  Targeting and tracing antigens in live cells with fluorescent nanobodies , 2006, Nature Methods.

[296]  F. Grosveld,et al.  Generation of heavy-chain-only antibodies in mice , 2006, Proceedings of the National Academy of Sciences.

[297]  J. Tommassen,et al.  Llama Single-Chain Antibody That Blocks Lipopolysaccharide Binding and Signaling: Prospects for Therapeutic Applications , 2006, Clinical and Vaccine Immunology.

[298]  P. Hudson,et al.  Latest technologies for the enhancement of antibody affinity. , 2006, Advanced drug delivery reviews.

[299]  E. Remaut,et al.  Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.

[300]  Fred C Tenover,et al.  Mechanisms of antimicrobial resistance in bacteria. , 2006, The American journal of medicine.

[301]  Lennart Hammarstrom,et al.  Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. , 2006, Vaccine.

[302]  L. Hammarström,et al.  Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries , 2006, Applied Microbiology and Biotechnology.

[303]  S. Muyldermans,et al.  Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor , 2006, Nature Medicine.

[304]  L. Wyns,et al.  Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[305]  M. Stocks.  Intracellular antibodies: a revolution waiting to happen? , 2006, Current opinion in molecular therapeutics.

[306]  T. Niewold,et al.  Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy , 2006, Applied Microbiology and Biotechnology.

[307]  Michael J. Osborn,et al.  Heavy-chain-only antibody expression and B-cell development in the mouse. , 2006, Critical reviews in immunology.

[308]  N. Matsuda,et al.  Systemic inflammatory response syndrome (SIRS): molecular pathophysiology and gene therapy. , 2006, Journal of Pharmacological Sciences.

[309]  G. van Ommen,et al.  Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. , 2006, Human molecular genetics.

[310]  F. V. van Zijderveld,et al.  Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea. , 2005, Veterinary microbiology.

[311]  L. Hammarström,et al.  Passive immunization by lactobacilli expressing single-chain antibodies against Streptococcus mutans , 2005, Molecular biotechnology.

[312]  H. Sprong,et al.  The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells , 2005, Journal of neurochemistry.

[313]  M. Harmsen,et al.  Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. , 2005, Vaccine.

[314]  Jennifer A. Smith,et al.  Supplementary Material References Subscriptions Permissions Email Alerts Expression of a Dromedary Heavy Chain-Only Antibody and B Cell Development in the Mouse , 2013 .

[315]  A. Messer,et al.  Intrabody applications in neurological disorders: progress and future prospects. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[316]  G. Vriend,et al.  Isolation of Llama Antibody Fragments for Prevention of Dandruff by Phage Display in Shampoo , 2005, Applied and Environmental Microbiology.

[317]  L. Trudel,et al.  Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. , 2005, ILAR journal.

[318]  P. Weissberg,et al.  Molecular and metabolic imaging of atherosclerosis. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[319]  J. W. Bos,et al.  Bactericidal Effects of a Fusion Protein of Llama Heavy-Chain Antibodies Coupled to Glucose Oxidase on Oral Bacteria , 2004, Antimicrobial Agents and Chemotherapy.

[320]  J. Kelly,et al.  A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. , 2004, Journal of molecular biology.

[321]  M. Papamichail,et al.  Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes , 2004, Cancer Immunology, Immunotherapy.

[322]  Serge Muyldermans,et al.  Efficient cancer therapy with a nanobody-based conjugate. , 2004, Cancer research.

[323]  W. Tatton,et al.  Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? , 2004, Drug discovery today.

[324]  L. Wyns,et al.  Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies , 2004, Journal of Biological Chemistry.

[325]  H. Karoui,et al.  Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. , 2003, Toxicon : official journal of the International Society on Toxinology.

[326]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[327]  W. Gibson.  Faculty Opinions recommendation of Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. , 2003 .

[328]  Shenghua Li,et al.  Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. , 2003, Journal of immunological methods.

[329]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[330]  T. Rabbitts,et al.  Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. , 2003, Journal of molecular biology.

[331]  K Kümmerer,et al.  Significance of antibiotics in the environment. , 2003, The Journal of antimicrobial chemotherapy.

[332]  T. Wilkins,et al.  Infection in Mice , 2003 .

[333]  L. Wyns,et al.  Single‐domain antibody fragments with high conformational stability , 2002, Protein science : a publication of the Protein Society.

[334]  J. Tanha,et al.  Selection of phage‐displayed llama single‐domain antibodies that transmigrate across human blood‐brain barrier endothelium , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[335]  J. Frère,et al.  β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae , 2001, Antimicrobial Agents and Chemotherapy.

[336]  C Cambillau,et al.  Thermal unfolding of a llama antibody fragment: a two-state reversible process. , 2001, Biochemistry.

[337]  E. Simões.  Respiratory syncytial virus infection , 1999, The Lancet.

[338]  H. Warner.  Apoptosis: A Two‐edged Sword in Aging , 1999, Annals of the New York Academy of Sciences.

[339]  K. Frei,et al.  Severity of symptoms and demyelination in MOG‐induced EAE depends on TNFR1 , 1999, European journal of immunology.

[340]  L. Wyns,et al.  Camel single‐domain antibody inhibits enzyme by mimicking carbohydrate substrate , 1998, Proteins.

[341]  Lode Wyns,et al.  Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies , 1998, The EMBO journal.

[342]  L. Wyns,et al.  Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies , 1997, FEBS letters.

[343]  I. Bahar,et al.  [Epidermal growth factor receptor]. , 1994, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[344]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[345]  J. Carlson,et al.  A new means of inducibly inactivating a cellular protein , 1988, Molecular and cellular biology.

[346]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.